An­oth­er biotech IPO set-up? Multi­na­tion­al biotech leaps from round to round, scoop­ing up cash at a blis­ter­ing pace

A short four months af­ter an­nounc­ing a $75 mil­lion haul in Se­ries B+ fundrais­ing, the multi­na­tion­al biotech Har­bour Bio­Med pulled in an­oth­er round of in­vest­ments and eclipsed the nine-dig­it mark in the process.

Har­bour com­plet­ed its Se­ries C fi­nanc­ing, the com­pa­ny an­nounced Thurs­day morn­ing, rais­ing $102.8 mil­lion and bring­ing its to­tal in­vest­ment sum to over $300 mil­lion since its found­ing in late 2016. The biotech plans to use the mon­ey to tran­si­tion ear­ly-stage can­di­dates from the dis­cov­ery phase, fund can­di­dates al­ready in the clin­ic, and prep late-stage can­di­dates for com­mer­cial­iza­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER